keyword
MENU ▼
Read by QxMD icon Read
search

CTCL

keyword
https://www.readbyqxmd.com/read/29775497/inflammatory-cytokines-and-peripheral-mediators-in-the-pathophysiology-of-pruritus-in-cutaneous-t-cell-lymphoma
#1
REVIEW
Daniel J Lewis, Simo Huang, Madeleine Duvic
Cutaneous T-cell lymphoma (CTCL) includes a diverse group of neoplasms, including mycosis fungoides and Sézary syndrome. One of the earliest and most common symptoms of CTCL is pruritus, which affects up to 88% of patients. The severity of pruritus can range from mild to very debilitating, producing tremendous discomfort and a significant decrease in quality of life. Patients with advanced disease, in particular, may experience a more chronic, intractable pruritus. However, the underlying mechanism of pruritus in CTCL remains unknown...
May 18, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29769011/evolving-strategies-for-the-treatment-of-t-cell-lymphoma-a-systematic-review-and-recent-patents
#2
Kamel Laribi, Mustapha Alani, Catherine Truong, Alix Baugier de Materre
OBJECTIVE: Mature T-cell lymphomas are a heterogeneous group of T-cell malignancies with a poor outcome. The discovery of new molecular biomarkers has led to the emergence of new drugs in recent years that target various signaling pathways. METHOD: We examined all pertinent published patents through 2015 that analyzed novel methods for the diagnosis and treatment of T cell lymphoma, as well as related published and unpublished studies. Selection criteria were established before data collection...
May 16, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29764863/extracorporeal-photochemotherapy-drives-monocyte-to-dendritic-cell-maturation-to-induce-anti-cancer-immunity
#3
Alessandra Ventura, Aaron Vassall, Eve Robinson, Renata Filler, Douglas Hanlon, Katrina Meeth, Harib Ezaldein, Michael Girardi, Olga Sobolev, Marcus W Bosenberg, Richard L Edelson
Extracorporeal photochemotherapy (ECP) is a cancer immunotherapy for cutaneous T cell lymphoma (CTCL) operative in more than 350 centers worldwide. While its efficacy and favorable safety profile have driven its widespread use, elucidation of its underlying mechanism has been difficult. In this study, we identify the principal contributors to the anti-cancer immunotherapeutic effects of ECP, with the goal of enhancing potency and broadening applicability to additional malignancies. First, we scaled down the clinical ECP leukocyte-processing device to mouse size...
May 15, 2018: Cancer Research
https://www.readbyqxmd.com/read/29758280/multi-kinase-inhibitor-with-anti-p38%C3%AE-activity-in-cutaneous-t-cell-lymphoma
#4
Xu Hannah Zhang, Sangkil Nam, Jun Wu, Chih-Hong Chen, Xuxiang Liu, Hongzhi Li, Timothy McKeithan, Qiang Gong, Wing C Chan, Hongwei Holly Yin, Yate-Ching Yuan, Raju Pillai, Christiane Querfeld, David Horne, Yuan Chen, Steven T Rosen
Current cutaneous T cell lymphoma (CTCL) therapies are marked by an abbreviated response, subsequent drug resistance, and poor prognosis for patients with advanced disease. An understanding of molecular regulators involved in CTCL is needed to develop effective targeted therapies. One candidate regulator is p38γ, a mitogen-activated protein kinase crucial for malignant T cell activity and growth. p38γ gene expression is selectively increased in CTCL patient samples as well as cell lines, but not in healthy T cells...
May 11, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29751003/special-at-rich-binding1-protein-satb1-in-malignant-t-cells
#5
Simon Fredholm, Andreas Willerslev-Olsen, Özcan Met, Linda Kubat, Maria Gluud, Sarah L Mathiasen, Christina Friese, Edda Blümel, David L Petersen, Tengpeng Hu, Claudia Nastasi, Lise M Lindahl, Terkild B Buus, Thorbjørn Krejsgaard, Mariusz A Wasik, Katharina L Kopp, Sergei B Koralov, Jenny L Persson, Charlotte M Bonefeld, Carsten Geisler, Anders Woetmann, Lars Iversen, Jurgen C Becker, Niels Odum
Deficient expression of Suppressor Special AT-rich Binding-1 (SATB1) hampers thymocyte development and results in inept T cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides (MF), the most frequent variant of cutaneous T cell lymphoma (CTCL). Here we report on a disease-stage-associated decrease of SATB1 expression and an inverse expression of STAT5 and SATB1 in situ. Importantly, STAT5 inhibited SATB1 expression through induction of miR-155. Decreased SATB1 expression triggered enhanced expression of IL-5 and IL-9 (but not IL-6 and IL-32) whereas increased SATB1 expression had the opposite effect indicating that the mir-155 target SATB1 is a repressor of IL-5 and IL-9 in malignant T cells...
May 8, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29743350/high-throughput-sequencing-of-the-t-cell-receptor-%C3%AE-gene-identifies-aggressive-early-stage-mycosis-fungoides
#6
Adele de Masson, John T O'Malley, Christopher P Elco, Sarah S Garcia, Sherrie J Divito, Elizabeth L Lowry, Marianne Tawa, David C Fisher, Phillip M Devlin, Jessica E Teague, Nicole R Leboeuf, Ilan R Kirsch, Harlan Robins, Rachael A Clark, Thomas S Kupper
Mycosis fungoides (MF), the most common cutaneous T cell lymphoma (CTCL) is a malignancy of skin-tropic memory T cells. Most MF cases present as early stage (stage I A/B, limited to the skin), and these patients typically have a chronic, indolent clinical course. However, a small subset of early-stage cases develop progressive and fatal disease. Because outcomes can be so different, early identification of this high-risk population is an urgent unmet clinical need. We evaluated the use of next-generation high-throughput DNA sequencing of the T cell receptor β gene ( TCRB ) in lesional skin biopsies to predict progression and survival in a discovery cohort of 208 patients with CTCL (177 with MF) from a 15-year longitudinal observational clinical study...
May 9, 2018: Science Translational Medicine
https://www.readbyqxmd.com/read/29742194/widespread-skin-necrosis-secondary-to-gemcitabine-therapy
#7
Patrick M Zito, Adrianna M Gonzalez, Joshua D Fox, Megan Cronin, Nicholas Mackrides, Robert S Kirsner, Anna J Nichols
Gemcitabine, a pyrimidine nucleoside analogue, is an oncologic agent used in the treatment of cutaneous T-cell lymphoma (CTCL). Common dermatologic reactions associated with gemcitabine include alopecia, mild skin rash, and mucositis but skin necrosis is exceptional. Herein we present an unusual case of widespread skin necrosis mimicking toxic epidermal necrolysis in a 45-year-old woman receiving gemcitabine therapy for stage IIIA cutaneous T-cell lymphoma. This is the first reported case of a TEN-like reaction subsequent to gemcitabine treatment...
May 1, 2018: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29733229/healthcare-resource-utilization-costs-of-care-and-treatment-of-mycosis-fungoides-cutaneous-t-cell-lymphoma-patterns-in-a-large-managed-care-population-a-retrospective-us-claims-based-analysis
#8
Yuen Tsang, Tao Gu, Gaurav Sharma, Susan Raspa, Bill Drake, Hiangkiat Tan
PURPOSE: To evaluate health care utilization, treatment patterns and costs among patients with mycosis fungoides-cutaneous T-cell lymphoma (MF-CTCL). METHODS: This retrospective cohort study queried the HealthCore Integrated Research Database to identify patients ≥18 years with ≥2 diagnoses of MF-CTCL (ICD-9-CM code 202.1x, 202.2x) between 07 January 2006 and 07 January 2013. Index date was defined as first MF-CTCL diagnosis. Patients were continuously enrolled ≥6 months before and ≥12 months after index date...
May 7, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29726727/epigenetic-therapy-and-dermatologic-disease-moving-beyond-ctcl
#9
Joshua S Mervis, Jean S McGee
The epigenetic regulation of gene expression is accomplished primarily through DNA methylation, histone modification, and gene silencing via the action of microRNAs. While previously very difficult to study, the field of epigenetics has been greatly facilitated by recent technological innovations. Alterations in the epigenome and epigenetic machinery are now known to be present in a variety of diseases, most notably cancers. Moreover, evidence has emerged that epigenetic dysregulation plays a causative role in disease pathogenesis...
May 4, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29719024/molecular-advances-in-cutaneous-t-cell-lymphoma
#10
Armando N Bastidas Torres, Safa Najidh, Cornelis P Tensen, Maarten H Vermeer
Cutaneous T-cell lymphoma (CTCL) is a group of malignancies derived from skin-homing T cells. Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common CTCL variants. In recent years, the genetic landscape of SS/MF has been characterized using genome-wide nextgeneration sequencing approaches. These studies have revealed that genes subjected to oncogenic mutations take part in cell cycle regulation, chromatin modification, Janus kinase (JAK)-signal transducer and activator of transcription protein (STAT) signaling, T-cell receptor (TCR)/ nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, and microtubule associated protein kinase (MAPK) signaling, which suggests that deregulation of these cellular processes underlies lymphomagenesis...
March 2018: Seminars in Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29704526/a-novel-gene-expression-analytics-based-approach-to-structure-aided-design-of-rexinoids-for-development-as-next-generation-cancer-therapeutics
#11
Bentley J Hanish, Jennifer F Hackney Price, Ichiro Kaneko, Ning Ma, Arjan van der Vaart, Carl E Wagner, Peter W Jurutka, Pamela A Marshall
Rexinoids are powerful ligands that bind to retinoid-X-receptors (RXRs) and show great promise as therapeutics for a wide range of diseases, including cancer. However, only one rexinoid, bexarotene (Targretin TM) has been successfully transitioned from the bench to the clinic and used to treat cutaneous T-cell lymphoma (CTCL). Our goal is to develop novel potent rexinoids with a less untoward side effect profile than bexarotene. To this end, we have synthesized a wide array of rexinoids with EC50 values and biological activity similar to bexarotene...
April 25, 2018: Steroids
https://www.readbyqxmd.com/read/29675945/epigenetically-enhanced-pdt-epdt-induces-significantly-higher-levels-of-multiple-extrinsic-pathway-apoptotic-factors-than-standard-pdt-resulting-in-greater-extrinsic-and-overall-apoptosis-of-ctcl
#12
Katrin A Salva, Youn H Kim, Ziba Rahbar, Gary S Wood
Aminolevulinate-based photodynamic therapy (ALA-PDT) selectively eliminates diseased tissues primarily through the induction of intrinsic apoptotic pathway. ALA-PDT is a first-line therapy for actinic keratosis, however, it is less effective for cutaneous T-cell lymphoma (CTCL). We have previously demonstrated that the resistance of CTCL to apoptosis correlates with decreased expression of death receptors such as FAS, and that methotrexate functions as an epigenetic regulator that re-establishes the susceptibility of CTCL to extrinsic pathway apoptosis...
April 20, 2018: Photochemistry and Photobiology
https://www.readbyqxmd.com/read/29606946/the-importance-of-excluding-cutaneous-t-cell-lymphomas-in-patients-with-a-working-diagnosis-of-papuloerythroderma-of-ofuji-a-case-series
#13
Anthony M Maher, Chloé E Ward, Steven Glassman, Ivan V Litvinov
Papuloerythroderma of Ofuji (PEO) is an erythroderma-like eruption with flat-topped papules that spare the skin folds (a "deck-chair sign" finding). Many infections, medications, and systemic diseases have been associated with PEO, including cutaneous T-cell lymphomas (CTCL). The relationship between the clinical presentation of PEO and CTCL remains poorly elucidated. Clinical, laboratory, and histopathological data were obtained from the Lymphoma Clinic at the Ottawa Hospital, Canada. We report 5 patients with deck-chair-sign-positive CTCL, mycosis fungoides, and Sézary syndrome variants...
January 2018: Case Reports in Dermatology
https://www.readbyqxmd.com/read/29599065/the-retinoid-x-receptor-agonist-9-cis-uab30-inhibits-cutaneous-t-cell-lymphoma-proliferation-through-the-skp2-p27kip1-axis
#14
Chu-Fang Chou, Yu-Hua Hsieh, Clinton J Grubbs, Venkatram R Atigadda, James A Mobley, Reinhard Dummer, Donald D Muccio, Isao Eto, Craig A Elmets, W Timothy Garvey, Pi-Ling Chang
BACKGROUND: Bexarotene (Targretin® ) is currently the only FDA approved retinoid X receptor (RXR) -selective agonist for the treatment of cutaneous T-cell lymphomas (CTCLs). The main side effects of bexarotene are hypothyroidism and elevation of serum triglycerides (TGs). The novel RXR ligand, 9-cis UAB30 (UAB30) does not elevate serum TGs or induce hypothyroidism in normal subjects. OBJECTIVES: To assess preclinical efficacy and mechanism of action of UAB30 in the treatment of CTCLs and compare its action with bexarotene...
March 15, 2018: Journal of Dermatological Science
https://www.readbyqxmd.com/read/29575114/american-council-on-ecp-ace-why-now
#15
Richard Edelson, Yanyun Wu, Jennifer Schneiderman
Stimulated by the scientific progress in deciphering the principal elements contributing to the clinical efficacy of extracorporeal photochemotherapy (ECP), the American Council on ECP (ACE) was formed, under the auspices of the American Society for Apheresis (ASFA), to develop a field-guiding Consensus Report. ACE is composed of thirty nationally recognized ECP experts, clinically spanning cancer, transplantation, and autoimmunity and scientifically bridging immunology, bioengineering, and hematology. The two-day meeting took place in Manhattan, April 13-14, 2017, and unanimous consensus on nine pivotal points is herein reported...
March 25, 2018: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/29572582/systemic-treatment-options-for-advanced-stage-mycosis-fungoides-and-s%C3%A3-zary-syndrome
#16
REVIEW
Louise Photiou, Carrie van der Weyden, Christopher McCormack, H Miles Prince
PURPOSE OF REVIEW: Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma. Globally, the most common subtypes of CTCL are mycosis fungoides and Sézary syndrome. CTCL can confer significant morbidity and even mortality in advanced disease. Here we review the current and potential future treatments for advanced-stage CTCL. RECENT FINDINGS: Heterogeneity of treatment choice has been demonstrated both in US and non-US centers. Systemic treatment choice is currently guided by prognostic features, incorporating stage, immunophenotypic and molecular findings, and patient-specific factors such as age and comorbidities...
March 23, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29559812/a-cohort-study-on-the-risk-of-lymphoma-and-skin-cancer-in-users-of-topical-tacrolimus-pimecrolimus-and-corticosteroids-joint-european-longitudinal-lymphoma-and-skin-cancer-evaluation-joelle-study
#17
Jordi Castellsague, Josephina G Kuiper, Anton Pottegård, Ingegärd Anveden Berglind, Daniel Dedman, Lia Gutierrez, Brian Calingaert, Myrthe Pp van Herk-Sukel, Jesper Hallas, Anders Sundström, Arlene M Gallagher, James A Kaye, Carolina Pardo, Kenneth J Rothman, Susana Perez-Gutthann
Background: There is a concern that topical tacrolimus and pimecrolimus, indicated for second-line treatment of atopic dermatitis, may increase the risk of lymphoma and skin cancer, particularly in children. Objective: The aim of this study was to compare incidence rates (IRs) of lymphoma and skin cancer between new users of topical tacrolimus or pimecrolimus and users of moderate- to high-potency topical corticosteroids (TCSs) and untreated subjects. Methods: This is a multicenter cohort study with frequency matching by strata of propensity scores in population databases in the Netherlands, Denmark, Sweden, and the UK...
2018: Clinical Epidemiology
https://www.readbyqxmd.com/read/29559342/microrna-signatures-in-diagnosis-and-prognosis-of-cutaneous-t-cell-lymphoma
#18
Xiaoyan Shen, Bo Wang, Kejia Li, Lili Wang, Xiaoqing Zhao, Feng Xue, Ruofei Shi, Jie Zheng
Cutaneous T cell lymphoma (CTCL) can have clinical and histological features resembling benign inflammatory dermatosis (BID) and can be difficult to diagnose. Very limited biomarkers are available for CTCL prognosis. We aimed to identify microRNA (miR) signatures to facilitate diagnostic and prognostic evaluations of CTCL. A cross-platform miR microarray identified 10 miRs that were differentially expressed between CTCL and BID patients. Subsequent RT-PCR validation was used to generate a 5-miR based diagnosing classifier, which showed high diagnostic accuracy in CTCL (AUC=0...
March 17, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29552279/brentuximab-vedotin-targeting-cd30-as-standard-in-ctcl
#19
EDITORIAL
H Miles Prince, Ashish Gautam, Youn H Kim
No abstract text is available yet for this article.
February 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29526921/-romidepsin-istodax-%C3%A2-for-intravenous-injection-10-mg-pharmacokinetics-pharmacodynamics-and-clinical-study-outcome
#20
Tokihiro Ro, Naoki Nakayama, Hiroyuki Achiwa, Tomoko Ohtsu
Romidepsin (Brand name: ISTODAX® for Injection 10 mg) is a novel antitumor drug that inhibits histone deacetylase (HDAC). Romidepsin strongly inhibited class I HDAC activity in vitro and demonstrated a strong antitumor activity against human tumor cell line xenograft in vivo. Based on its demonstrated efficacy against T-cell lymphoma in early clinical studies, multicenter phase II clinical studies in overseas with romidepsin were conducted in patients with cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), followed by approval for the treatment of CTCL and PTCL in the U...
2018: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
keyword
keyword
43981
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"